

Michael A Barry

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6495808/publications.pdf>

Version: 2024-02-01

105
papers

6,233
citations

87843

38
h-index

69214

77
g-index

109
all docs

109
docs citations

109
times ranked

5842
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 1 | Activation of programmed cell death (apoptosis) by cisplatin, other anticancer drugs, toxins and hyperthermia. <i>Biochemical Pharmacology</i> , 1990, 40, 2353-2362. | 2.0 | 845 |
| 2 | Toward cell-targeting gene therapy vectors: Selection of cell-binding peptides from random peptide-presenting phage libraries. <i>Nature Medicine</i> , 1996, 2, 299-305. | 15.2 | 343 |
| 3 | Reprogrammed viruses as cancer therapeutics: targeted, armed and shielded. <i>Nature Reviews Microbiology</i> , 2008, 6, 529-540. | 13.6 | 342 |
| 4 | Protection against mycoplasma infection using expression-library immunization. <i>Nature</i> , 1995, 377, 632-635. | 13.7 | 313 |
| 5 | Poly(ethylenimine)-mediated transfection: A new paradigm for gene delivery. <i>Journal of Biomedical Materials Research Part B</i> , 2000, 51, 321-328. | 3.0 | 293 |
| 6 | Lentiviral vectors: basic to translational. <i>Biochemical Journal</i> , 2012, 443, 603-618. | 1.7 | 258 |
| 7 | Evaluation of polyethylene glycol modification of first-generation and helper-dependent adenoviral vectors to reduce innate immune responses. <i>Molecular Therapy</i> , 2005, 11, 66-79. | 3.7 | 225 |
| 8 | Comparison of visible and near-infrared wavelength-excitable fluorescent dyes for molecular imaging of cancer. <i>Journal of Biomedical Optics</i> , 2007, 12, 024017. | 1.4 | 193 |
| 9 | Current Advances and Future Challenges in Adenoviral Vector Biology and Targeting. <i>Current Gene Therapy</i> , 2007, 7, 189-204. | 0.9 | 174 |
| 10 | Semaphorin III can repulse and inhibit adult sensory afferents in vivo. <i>Nature Medicine</i> , 1997, 3, 1398-1401. | 15.2 | 135 |
| 11 | Advances and Future Challenges in Adenoviral Vector Pharmacology and Targeting. <i>Current Gene Therapy</i> , 2011, 11, 241-258. | 0.9 | 131 |
| 12 | IRE1A Stimulates Hepatocyte-Derived Extracellular Vesicles That Promote Inflammation in Mice With Steatohepatitis. <i>Gastroenterology</i> , 2020, 159, 1487-1503.e17. | 0.6 | 105 |
| 13 | Metabolically biotinylated adenovirus for cell targeting, ligand screening, and vector purification. <i>Molecular Therapy</i> , 2003, 8, 688-700. | 3.7 | 104 |
| 14 | Chemical Modification with High Molecular Weight Polyethylene Glycol Reduces Transduction of Hepatocytes and Increases Efficacy of Intravenously Delivered Oncolytic Adenovirus. <i>Human Gene Therapy</i> , 2009, 20, 975-988. | 1.4 | 101 |
| 15 | Modification of Adenoviral Vectors With Polyethylene Glycol Modulates In Vivo Tissue Tropism and Gene Expression. <i>Molecular Therapy</i> , 2008, 16, 1276-1282. | 3.7 | 95 |
| 16 | Avidin-based targeting and purification of a protein IX-modified, metabolically biotinylated adenoviral vector. <i>Molecular Therapy</i> , 2004, 9, 942-954. | 3.7 | 87 |
| 17 | Macrophage Depletion Combined with Anticoagulant Therapy Increases Therapeutic Window of Systemic Treatment with Oncolytic Adenovirus. <i>Cancer Research</i> , 2008, 68, 5896-5904. | 0.4 | 86 |
| 18 | A chimeric adenovirus vector encoding reovirus attachment protein $\hat{A}1$ targets cells expressing junctional adhesion molecule 1. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2004, 101, 6188-6193. | 3.3 | 79 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 19 | Generation of a Kupffer Cell-evading Adenovirus for Systemic and Liver-directed Gene Transfer. <i>Molecular Therapy</i> , 2011, 19, 1254-1262. | 3.7 | 77 |
| 20 | Metabolic Biotinylation of Secreted and Cell Surface Proteins from Mammalian Cells. <i>Biochemical and Biophysical Research Communications</i> , 2001, 281, 993-1000. | 1.0 | 72 |
| 21 | Polyethylene Glycol Modification of Adenovirus Reduces Platelet Activation, Endothelial Cell Activation, and Thrombocytopenia. <i>Human Gene Therapy</i> , 2007, 18, 837-848. | 1.4 | 72 |
| 22 | Adenovirus Activates Complement by Distinctly Different Mechanisms In Vitro and In Vivo: Indirect Complement Activation by Virions In Vivo. <i>Journal of Virology</i> , 2009, 83, 5648-5658. | 1.5 | 72 |
| 23 | Identification of Adenovirus Serotype 5 Hexon Regions That Interact with Scavenger Receptors. <i>Journal of Virology</i> , 2012, 86, 2293-2301. | 1.5 | 69 |
| 24 | Comparison of adenovirus fiber, protein IX, and hexon capsomeres as scaffolds for vector purification and cell targeting. <i>Virology</i> , 2006, 349, 453-462. | 1.1 | 67 |
| 25 | Cryo-EM structure of human adenovirus D26 reveals the conservation of structural organization among human adenoviruses. <i>Science Advances</i> , 2017, 3, e1602670. | 4.7 | 64 |
| 26 | Characterization of human adenovirus serotypes 5, 6, 11, and 35 as anticancer agents. <i>Virology</i> , 2009, 394, 311-320. | 1.1 | 61 |
| 27 | Comparison of Replication-Competent, First Generation, and Helper-Dependent Adenoviral Vaccines. <i>PLoS ONE</i> , 2009, 4, e5059. | 1.1 | 61 |
| 28 | An optimized method for the chemiluminescent detection of alkaline phosphatase levels during osteodifferentiation by bone morphogenetic protein 2. <i>Journal of Cellular Biochemistry</i> , 2001, 80, 532-537. | 1.2 | 60 |
| 29 | Metabolic Biotinylation of Recombinant Proteins in Mammalian Cells and in Mice. <i>Molecular Therapy</i> , 2000, 1, 96-104. | 3.7 | 59 |
| 30 | Oral immunization of rhesus macaques with adenoviral HIV vaccines using enteric-coated capsules. <i>Vaccine</i> , 2007, 25, 8687-8701. | 1.7 | 52 |
| 31 | Protection against Divergent Influenza H1N1 Virus by a Centralized Influenza Hemagglutinin. <i>PLoS ONE</i> , 2011, 6, e18314. | 1.1 | 51 |
| 32 | Effects of Shielding Adenoviral Vectors with Polyethylene Glycol on Vector-Specific and Vaccine-Mediated Immune Responses. <i>Human Gene Therapy</i> , 2008, 19, 1369-1382. | 1.4 | 50 |
| 33 | Circulating Antibodies and Macrophages as Modulators of Adenovirus Pharmacology. <i>Journal of Virology</i> , 2013, 87, 3678-3686. | 1.5 | 49 |
| 34 | Comparison of Gene Delivery to the Kidney by Adenovirus, Adeno-Associated Virus, and Lentiviral Vectors After Intravenous and Direct Kidney Injections. <i>Human Gene Therapy</i> , 2019, 30, 1559-1571. | 1.4 | 47 |
| 35 | Generation of a Hypomorphic Model of Propionic Acidemia Amenable to Gene Therapy Testing. <i>Molecular Therapy</i> , 2013, 21, 1316-1323. | 3.7 | 46 |
| 36 | Infectious SIV resides in adipose tissue and induces metabolic defects in chronically infected rhesus macaques. <i>Retrovirology</i> , 2016, 13, 30. | 0.9 | 46 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 37 | Infection and Killing of Multiple Myeloma by Adenoviruses. <i>Human Gene Therapy</i> , 2010, 21, 179-190. | 1.4 | 44 |
| 38 | Low Seroprevalent Species D Adenovirus Vectors as Influenza Vaccines. <i>PLoS ONE</i> , 2013, 8, e73313. | 1.1 | 44 |
| 39 | Adeno-Associated Virus Serotype 8 Gene Transfer Rescues a Neonatal Lethal Murine Model of Propionic Acidemia. <i>Human Gene Therapy</i> , 2011, 22, 477-481. | 1.4 | 39 |
| 40 | Species D Adenoviruses as Oncolytics against B-cell Cancers. <i>Clinical Cancer Research</i> , 2011, 17, 6712-6722. | 3.2 | 39 |
| 41 | Suppression-Replacement <i>KCNQ1</i> Gene Therapy for Type 1 Long QT Syndrome. <i>Circulation</i> , 2021, 143, 1411-1425. | 1.6 | 39 |
| 42 | Precision gene editing technology and Applications in nephrology. <i>Nature Reviews Nephrology</i> , 2018, 14, 663-677. | 4.1 | 38 |
| 43 | Amplified and Persistent Immune Responses Generated by Single-Cycle Replicating Adenovirus Vaccines. <i>Journal of Virology</i> , 2015, 89, 669-675. | 1.5 | 37 |
| 44 | Replicating Single-Cycle Adenovirus Vectors Generate Amplified Influenza Vaccine Responses. <i>Journal of Virology</i> , 2017, 91, . | 1.5 | 36 |
| 45 | Expanded Anticancer Therapeutic Window of Hexon-modified Oncolytic Adenovirus. <i>Molecular Therapy</i> , 2009, 17, 2121-2130. | 3.7 | 35 |
| 46 | I ₁ la deleted adenovirus as a single-cycle genome replicating vector. <i>Virology</i> , 2014, 462-463, 158-165. | 1.1 | 35 |
| 47 | Long-Term Sex-Biased Correction of Circulating Propionic Acidemia Disease Markers by Adeno-Associated Virus Vectors. <i>Human Gene Therapy</i> , 2015, 26, 153-160. | 1.4 | 35 |
| 48 | Rapid Construction of Capsid-Modified Adenoviral Vectors Through Bacteriophage λ Red Recombination. <i>Human Gene Therapy</i> , 2004, 15, 1125-1130. | 1.4 | 34 |
| 49 | Development and characterization of enhanced green fluorescent protein and luciferase expressing cell line for non-destructive evaluation of tissue engineering constructs. <i>Biomaterials</i> , 2004, 25, 5809-5819. | 5.7 | 33 |
| 50 | Cryoelectron Microscopy of Protein IX-Modified Adenoviruses Suggests a New Position for the C Terminus of Protein IX. <i>Journal of Virology</i> , 2006, 80, 11881-11886. | 1.5 | 33 |
| 51 | Short-Term Rescue of Neonatal Lethality in a Mouse Model of Propionic Acidemia by Gene Therapy. <i>Human Gene Therapy</i> , 2009, 20, 169-180. | 1.4 | 33 |
| 52 | Characterization of species C human adenovirus serotype 6 (Ad6). <i>Virology</i> , 2011, 412, 19-27. | 1.1 | 32 |
| 53 | Expression library immunization to discover and improve vaccine antigens. <i>Immunological Reviews</i> , 2004, 199, 68-83. | 2.8 | 30 |
| 54 | Selection of Muscle-Binding Peptides from Context-Specific Peptide-Presenting Phage Libraries for Adenoviral Vector Targeting. <i>Journal of Virology</i> , 2005, 79, 13667-13672. | 1.5 | 27 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 55 | Retargeting adenoviruses for therapeutic applications and vaccines. <i>FEBS Letters</i> , 2020, 594, 1918-1946. | 1.3 | 27 |
| 56 | Protection against Mucosal SHIV Challenge by Peptide and Helper-Dependent Adenovirus Vaccines. <i>Viruses</i> , 2009, 1, 920-938. | 1.5 | 26 |
| 57 | Targeting Adenoviruses with Factor Xa-Single-Chain Antibody Fusion Proteins. <i>Human Gene Therapy</i> , 2010, 21, 739-749. | 1.4 | 26 |
| 58 | Single-cycle adenovirus vectors in the current vaccine landscape. <i>Expert Review of Vaccines</i> , 2018, 17, 1-11. | 2.0 | 25 |
| 59 | Natural killer T cell and TLR9 agonists as mucosal adjuvants for sublingual vaccination with clade C HIV-1 envelope protein. <i>Vaccine</i> , 2014, 32, 6934-6940. | 1.7 | 23 |
| 60 | Treatment of osteoarthritis using a helper-dependent adenoviral vector retargeted to chondrocytes. <i>Molecular Therapy - Methods and Clinical Development</i> , 2016, 3, 16008. | 1.8 | 23 |
| 61 | Biotinylated gene therapy vectors. <i>Expert Opinion on Biological Therapy</i> , 2003, 3, 925-940. | 1.4 | 22 |
| 62 | Comparison of Systemic and Mucosal Immunization with Helper-Dependent Adenoviruses for Vaccination against Mucosal Challenge with SHIV. <i>PLoS ONE</i> , 2013, 8, e67574. | 1.1 | 22 |
| 63 | Increased Transduction of Skeletal Muscle Cells by Fibroblast Growth Factor-Modified Adenoviral Vectors. <i>Human Gene Therapy</i> , 2006, 17, 314-320. | 1.4 | 20 |
| 64 | Enhancement of Mucosal Immunogenicity of Viral Vected Vaccines by the NKT Cell Agonist Alpha-Galactosylceramide as Adjuvant. <i>Vaccines</i> , 2014, 2, 686-706. | 2.1 | 20 |
| 65 | Selection of chronic lymphocytic leukemia binding peptides. <i>Cancer Research</i> , 2003, 63, 5213-7. | 0.4 | 20 |
| 66 | Evaluation of polymer shielding for adenovirus serotype 6 (Ad6) for systemic virotherapy against human prostate cancers. <i>Molecular Therapy - Oncolytics</i> , 2016, 3, 15021. | 2.0 | 19 |
| 67 | Transgene Expression and Host Cell Responses to Replication-Defective, Single-Cycle, and Replication-Competent Adenovirus Vectors. <i>Genes</i> , 2017, 8, 79. | 1.0 | 19 |
| 68 | Improving Molecular Therapy in the Kidney. <i>Molecular Diagnosis and Therapy</i> , 2020, 24, 375-396. | 1.6 | 18 |
| 69 | Real-Time Dynamic Imaging of Virus Distribution In Vivo. <i>PLoS ONE</i> , 2011, 6, e17076. | 1.1 | 18 |
| 70 | Dysregulated miRNAs and their pathogenic implications for the neurometabolic disease propionic acidemia. <i>Scientific Reports</i> , 2017, 7, 5727. | 1.6 | 16 |
| 71 | Oncolytic adenovirus Ad657 for systemic virotherapy against prostate cancer. <i>Oncolytic Virotherapy</i> , 2018, Volume 7, 43-51. | 6.0 | 14 |
| 72 | A Replicating Single-Cycle Adenovirus Vaccine Against Ebola Virus. <i>Journal of Infectious Diseases</i> , 2018, 218, 1883-1889. | 1.9 | 14 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 73 | Systemic delivery of therapeutic viruses. <i>Current Opinion in Molecular Therapeutics</i> , 2009, 11, 411-20. | 2.8 | 14 |
| 74 | Effects of Adeno-Associated Virus Serotype and Tissue-Specific Expression on Circulating Biomarkers of Propionic Acidemia. <i>Human Gene Therapy</i> , 2014, 25, 837-843. | 1.4 | 13 |
| 75 | CD46-Mediated Transduction of a Species D Adenovirus Vaccine Improves Mucosal Vaccine Efficacy. <i>Human Gene Therapy</i> , 2014, 25, 364-374. | 1.4 | 13 |
| 76 | Structure-based assessment of protein-protein interactions and accessibility of protein IX in adenoviruses with implications for antigen display. <i>Virology</i> , 2018, 516, 102-107. | 1.1 | 13 |
| 77 | Mining the Adenovirus "Virome" for Systemic Oncolytics. <i>Current Pharmaceutical Biotechnology</i> , 2012, 13, 1804-1808. | 0.9 | 12 |
| 78 | A Vector Host System to Fingerprint Virus Tropism. <i>Human Gene Therapy</i> , 2012, 23, 1116-1126. | 1.4 | 12 |
| 79 | Comparison of Adenoviruses as Oncolytics and Cancer Vaccines in an Immunocompetent B Cell Lymphoma Model. <i>Human Gene Therapy</i> , 2011, 22, 1095-1100. | 1.4 | 11 |
| 80 | Divergent HIV-1-Directed Immune Responses Generated by Systemic and Mucosal Immunization with Replicating Single-Cycle Adenoviruses in Rhesus Macaques. <i>Journal of Virology</i> , 2019, 93, . | 1.5 | 11 |
| 81 | Genetic Adjuvants in Replicating Single-Cycle Adenovirus Vectors Amplify Systemic and Mucosal Immune Responses against HIV-1 Envelope. <i>Vaccines</i> , 2020, 8, 64. | 2.1 | 11 |
| 82 | Retargeted and detargeted adenovirus for gene delivery to the muscle. <i>Virology</i> , 2018, 514, 118-123. | 1.1 | 10 |
| 83 | Mucoadhesive wafers composed of binary polymer blends for sublingual delivery and preservation of protein vaccines. <i>Journal of Controlled Release</i> , 2021, 330, 427-437. | 4.8 | 10 |
| 84 | Structural Organization and Protein-Protein Interactions in Human Adenovirus Capsid. <i>Sub-Cellular Biochemistry</i> , 2021, 96, 503-518. | 1.0 | 10 |
| 85 | Metabolic perturbations mediated by propionyl-CoA accumulation in organs of mouse model of propionic acidemia. <i>Molecular Genetics and Metabolism</i> , 2021, 134, 257-266. | 0.5 | 10 |
| 86 | <i>Ex Vivo</i> and <i>In Vivo</i> CD46 Receptor Utilization by Species D Human Adenovirus Serotype 26 (HAdV26). <i>Journal of Virology</i> , 2022, 96, JVI0082621. | 1.5 | 9 |
| 87 | Comparison of the Life Cycles of Genetically Distant Species C and Species D Human Adenoviruses Ad6 and Ad26 in Human Cells. <i>Journal of Virology</i> , 2015, 89, 12401-12417. | 1.5 | 8 |
| 88 | Comparison of systemic and mucosal immunization with replicating Single cycle Adenoviruses. <i>Global Vaccines and Immunology</i> , 2018, 3, . | 0.2 | 8 |
| 89 | Mucosal vaccination by adenoviruses displaying reovirus sigma 1. <i>Virology</i> , 2015, 482, 60-66. | 1.1 | 7 |
| 90 | Imaging Luciferase-Expressing Viruses. <i>Methods in Molecular Biology</i> , 2012, 797, 79-87. | 0.4 | 6 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 91 | Comparison of Liver Detargeting Strategies for Systemic Therapy with Oncolytic Adenovirus Serotype 5. <i>Biomedicines</i> , 2017, 5, 46. | 1.4 | 5 |
| 92 | Breaking tolerance with engineered class I antigen-presenting molecules. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 3136-3145. | 3.3 | 5 |
| 93 | A Replicating Single-Cycle Adenovirus Vaccine Effective against <i>Clostridium difficile</i> . <i>Vaccines</i> , 2020, 8, 470. | 2.1 | 5 |
| 94 | Poly(ethylenimine)-mediated transfection: A new paradigm for gene delivery. <i>Journal of Biomedical Materials Research Part B</i> , 2000, 51, 321-328. | 3.0 | 5 |
| 95 | Modulating Oncolytic Adenovirus Immunotherapy by Driving Two Axes of the Immune System by Expressing 4-1BBL and CD40L. <i>Human Gene Therapy</i> , 2022, 33, 250-261. | 1.4 | 5 |
| 96 | Selection of Peptides on Phage. , 2003, , 547-579. | | 3 |
| 97 | Response to Adhikary et al.. <i>Virology</i> , 2012, 424, 2. | 1.1 | 3 |
| 98 | Minimally invasive monitoring of CD4 T cells at multiple mucosal tissues after intranasal vaccination in rhesus macaques. <i>PLoS ONE</i> , 2017, 12, e0188807. | 1.1 | 3 |
| 99 | An optimized method for the chemiluminescent detection of alkaline phosphatase levels during osteodifferentiation by bone morphogenetic protein 2. , 2001, 80, 532. | | 2 |
| 100 | Short-term Rescue of Neonatal Lethality in a Mouse Model of Propionic Acidemia by Gene Therapy. <i>Human Gene Therapy</i> , 2008, . | 1.4 | 2 |
| 101 | A novel codon-optimized SIV gag-pol immunogen for gene-based vaccination. <i>Virology Reports</i> , 2015, 5, 47-55. | 0.4 | 1 |
| 102 | Unlocking loxP to Track Genome Editing In Vivo. <i>Genes</i> , 2021, 12, 1204. | 1.0 | 1 |
| 103 | Refined Capsid Structure of Human Adenovirus D26 at 3.4 Å... Resolution. <i>Viruses</i> , 2022, 14, 414. | 1.5 | 1 |
| 104 | Adenoviral Vector Targeting via Mitigation of Liver Sequestration. , 2016, , 293-317. | | 0 |
| 105 | Recent advances towards gene therapy for propionic acidemia: translation to the clinic. <i>Expert Review of Precision Medicine and Drug Development</i> , 2019, 4, 229-237. | 0.4 | 0 |